Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
64
Language
English
Published on
31/01/25
You may also be interested by these reports :
17/07/25
The reported FY2024-25 numbers fell short of our expectations due to higher-than-anticipated operating and other financial expenses. In the near ...
14/07/25
Drägerwerk’s Q2 2025 preliminary results fell short of our estimates. Net sales increased by 1.8%, with a 5% growth in the medical division ...
11/07/25
Given the numerous new product launches, high adoption of existing products, increased presence in point-of-care testing and robust balance sheet, we ...
07/07/25
Sartorius (BUY; Germany), a historically pristine business, has fallen off its perch. Following the big and expensive bet on Polyplus, Sartorius ...